Skip to search boxSkip to navigationSkip to main content

Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs

  • I. Hartyánszky
    ,
  • H. Kalász(corresponding author)
    ,
  • E. Adeghate
    ,
  • Zs Gulyás
    ,
  • M. Y. Hasan
    ,
  • K. Tekes
*Corresponding author for this work
  • Semmelweis University
    ,
  • United Arab Emirates University
    ,
  • Thalesnano, Inc.
Research Output:
Contribution to journal
Review article
Research
Peer-review

Abstract

Decarboxylation, reduction and hydrolysis can yield active metabolites from the parent drug. Major therapeutic indications and metabolic routes of these drugs are reviewed. Changes in the logP values (determined and calculated) from the parent drug to the active metabolite show certain characteristics in comparison to other phase I metabolic alterations. Metabolic decarboxylation of parent drug is commonly associated with increase in lipophilicity. However, in some cases, decarboxylation may cause a reduction in lipophilicity. Ester hydrolysis generally unmasks either the polar carboxylic or hydroxyl group with the outcome of an increase in hydrophilicity. On the contrary, hydrolysis of phosphate ester means a huge increase in the lipophilic character of the drug, as the highly polar phosphate group is removed.

Research Output Information

Output type

Research Output:
Contribution to journal
Review article
Research
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 835-862 (28 pages)

Journal (Volume, Issue Number)

Current Drug Metabolism (Volume 13, Issue 6)

Publication milestones

  • Published - 07/2012

Publication status

Published - 07/2012

ISSN

1389-2002

Publication IDs

  • Scopus: 84863655870
  • PubMed: 22571480

Publication metrics

Metrics

SciVal
FWCI
0.26
Scopus
citations

PlumX, opens in new tab

Citation count
5
Captures
20